Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008
27
Additional paid-in capital 59,201 58,984
Other comprehensive income 28 86
Deficit accumulated during the
development stage (39,370) (35,492)
Total shareholders' equity 19,886 23,605
Total liabilities and shareholders'
equity $ 22,594 $ 26,038
ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
Three months
Year ended December 31, ended March 31,
2007 2006 2008 2007
Unaudited
Operating expenses:
Research and development, net $ 6,400 $ 4,781 $ 2,389 $ 1,161
Marketing and business
development 1,742 1,504 511 375
General and administrative 2,903 1,860 829 680
Operating loss 11,045 8,145 3,729 2,216
Financial expenses (income),
net 3,616 (538) 149 (200)
Net loss $ 14,661 $ 7,607 $ 3,878 $ 2,016
Basic and diluted net loss
per Ordinary share $ 1.32 $ 2.98 $ 0.33 $ 0.23
Weighted average number of
Ordinary shares used to
compute basic and diluted
net loss per Ordinary share 11,142,149 2,551,860 11,920,401 8,874,841
Contact: Media
Rachel Spielman
T: +1-212-583-2714
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
(Date:5/21/2013)... May 21, 2013 Clinverse, ... company for clinical trials, announced today it has ... LLC. Clinverse’s ClinPay® FLS eClinical commerce platform ... process. SpendMD ™, Aggregate Spend Solutions’ ... for tracking and reporting transfer of value at ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Personal Genome Diagnostics Inc. (PGDx), today announced ... expertise in genomic analysis of defined cancer subtypes ... Blueprint Medicines. PGDx is an innovator in conducting ... tumors, and Blueprint Medicines is an expert in ... defined patient population. "This collaboration brings ...
(Date:5/21/2013)... Inflamax scientists worked closely with ... design the study, which will provide critical insight ... used in the study of allergy treatments, the ... (NAC) models. Although both the models are well ... no direct comparison between the allergic responses evoked ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2[0] Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC[0] Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions[0] Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets[0] Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... GeneLink Biosciences, Inc. (OTCBB: GNLK), a leading consumer ... the stock of its wholly owned direct-selling subsidiary ... (OTCBB: WELL), another public company operating in the ... and Capsalus executed definitive agreements for the sale ...
... 2012 Senior analysts from The Advisory Board Company,s ... Vegas preparing to provide an immediate analysis of the ... Management Systems Society,s HIMSS12 Annual Conference and Exhibition, which ... http://photos.prnewswire.com/prnh/20110802/PH45999LOGO ) By Monday, the ...
Cached Biology Technology:GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 2Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy 3(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4... different gene mutations, but just how these mutations contribute to ... new clue comes from scientists at the University of North ... Their research indicates that early life sun exposure, from birth ... melanomas with BRAF gene mutations. A different mutation, on the ...
... were estimated to be living with Alzheimer’s disease in 2006, ... Hopkins Bloomberg School of Public Health. The researchers also concluded ... than 106 million by 2050. By that time, 43 percent ... to that of a nursing home. The findings were presented ...
... at x-rays of hands, searching out the telltale signs of ... arthritis. With these clinical features at his side, he turns ... genome – to figure out what makes these people susceptible ... finally closed the circle between key genes identified in his ...
Cached Biology News:Sun exposure early in life linked to specific skin cancer gene mutation 2Alzheimer's disease to quadruple worldwide by 2050 2Breakthrough developments in rheumatoid arthritis reported 2Breakthrough developments in rheumatoid arthritis reported 3Breakthrough developments in rheumatoid arthritis reported 4Form: Ready to use Applications: ELISA...
Request Info...
Form: Concentrated Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |